Kishtagari, Ashwin http://orcid.org/0000-0003-1149-4571
Khan, M. A. Wasay
Li, Yajing
Vlasschaert, Caitlyn
Marneni, Naimisha
Silver, Alexander J. http://orcid.org/0000-0001-8255-3140
von Beck, Kelly http://orcid.org/0000-0001-8880-5652
Spaulding, Travis
Stockton, Shannon
Snider, Christina
Sochacki, Andrew
Dorand, Dixon
Mack, Taralynn M.
Ferrell, P. Brent Jr
Xu, Yaomin
Bejan, Cosmin A. http://orcid.org/0000-0001-5107-0584
Savona, Michael R.
Bick, Alexander G. http://orcid.org/0000-0001-5824-9595
Article History
Received: 5 September 2023
Revised: 15 December 2023
Accepted: 21 December 2023
First Online: 15 January 2024
Competing interests
: A.K. Consultancy: CTI Biopharma, Morphosys, Geron, Rigel. M.R.S.: Membership on a Board or Advisory Committee: Abbvie, Bristol Myers Squibb, CTI, Forma, Geron, Karyopharm, Novartis, Ryvu, Sierra Oncology, Taiho, Takeda, TG Therapeutics; Patents and Royalties: Boehringer Ingelheim; Research Funding: ALX Oncology, Astex, Incyte, Takeda, TG Therapeutics; Equity Ownership: Karyopharm, Ryvu; Consultancy: Forma, Karyopharm, Ryvu. P.B.F. research funding from Incyte, Astex Pharmaceuticals, and Forma Therapeutics. A.G.B. is a co-founder, equity holder, and on the scientific advisory board of TenSixteen Bio. The remaining authors declare no competing interests.